Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic myeloid leukaemia; Leukaemia
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 11 May 2017 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 12 May 2016 Planned number of patients changed from 33 to 50.